Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?

19 Aug 2015

Abstract excerpt

CONTEXT: The separation of benign from malignant mesothelial proliferations is crucial to patient care but is frequently morphologically difficult. OBJECTIVE: To briefly review adjunctive tests claimed to be useful in this setting and to examine in detail 2 new tests: p16 fluorescence in situ hybridization (FISH) and BRCA1-associated protein 1 (BAP1) immunohistochemistry. DESIGN: Literature review with emphasis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Occupational and environmental lung diseases
Share to Pleural and Pulmonary Diseases
Share to Soft tissue tumor case studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26288396
DOI: 10.5858/arpa.2015-0240-sa

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?PMID 26288396Read ↗

The Separation of Benign and Malignant Mesothelial ProliferationsSemantic proximity Read ↗

Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.Semantic proximity Read ↗

Malignant mesothelioma in situ: diagnostic and clinical considerations.Semantic proximity Read ↗

The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma.Semantic proximity Read ↗

BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.Semantic proximity Read ↗

FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesotheliomaSemantic proximity Read ↗

Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions.Semantic proximity Read ↗

A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural MesotheliomasSemantic proximity Read ↗

Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesotheliomaSemantic proximity Read ↗

Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?Semantic proximity Read ↗

Progression of Sarcomatoid Mesothelioma from Mesothelioma In Situ: A Case Report on Morphologic Changes during a Nine-month Interval and Careful Observation of Cytology in Early- stage MesotheliomaSemantic proximity Read ↗

Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant MesotheliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.